Shots:

• The P-III (VALOR-HCM) study evaluates mavacamten vs PBO in a ratio (1:1) in 100 adults with obstructive HCM who are eligible for SRT
• The trial met its 1EPs i.e., the proportion of patients who proceed with SRT & remained SRT-guideline eligible (LVOT gradient of ≥50mmHg and NYHA Class III-IV) @16wk. The 2EPs include impact on exercise gradient LVOT, NYHA Class, KCCQ & biomarkers @16wk. The safety was consistent with previous studies
• The company is planning to share the results with regulatory authorities. In pre-clinical/clinical studies, the therapy reduced biomarkers of cardiac wall stress lessened excessive cardiac contractility, increased diastolic compliance, and lessened LVOT gradients

 Ref: Businesswire | Image: BMS